Last reviewed · How we verify
NCT05178342: LUCAS
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
Terminated
Phase 2
Last updated 13 August 2024
What this trial tests
Phase 2 trial testing CA-4948 in Myelodysplastic Syndromes in 38 participants. Terminated before completion.
Timeline
1 January 2022
Primary endpoint
31 July 2024
31 July 2024
31 July 2024
Quick facts
| Lead sponsor | University of Leipzig |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 January 2022 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 15 locations across Germany |
Drugs / interventions tested
- CA-4948 — full drug profile →
Conditions studied
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Anemia — all drugs for Anemia →
Sponsor
University of Leipzig
Who can join
18 and older, any sex, with Myelodysplastic Syndromes or Anemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anemia in LR-MDS patients
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS, Pratz KW, Lai C. · · 2023 · cited 151× · PMID 36966300 · DOI 10.1186/s13045-023-01424-6 -
The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms.
Balandrán JC, Lasry A, Aifantis I. · · 2023 · cited 34× · PMID 37052531 · DOI 10.1158/2643-3230.bcd-22-0176 -
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233 -
Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD, Verma A. · · 2022 · cited 14× · PMID 36485128 · DOI 10.1182/hematology.2022000350 -
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
Guidetti F, Arribas AJ, Sartori G, Spriano F, et al · · 2023 · cited 12× · PMID 36675328 · DOI 10.3390/jcm12020399 -
Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer.
Feng Y, Chen C, Shao A, Wu L, et al · · 2024 · cited 11× · PMID 39807338 · DOI 10.1016/j.apsb.2024.09.008 -
Next-generation therapy for lower-risk MDS.
Sébert M. · · 2023 · cited 5× · PMID 38066862 · DOI 10.1182/hematology.2023000520 -
RNA binding protein-directed control of leukemic stem cell evolution and function.
Joshi P, Keyvani Chahi A, Liu L, Moreira S, et al · · 2024 · cited 3× · PMID 39175825 · DOI 10.1002/hem3.116
Verify or expand the search:
- PubMed search for NCT05178342
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CA-4948
Trials testing the same drug.
- NCT05187182 — CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Canc · Phase 1 · recruiting
Other recruiting trials for Myelodysplastic Syndromes
Currently open trials in the same condition.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
- NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
- NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
Other University of Leipzig trials
Trials by the same sponsor.
- NCT07155564 — Validation of Energy Expenditure Measures Study · recruiting
- NCT06656832 — Peripheral Drivers of Heart Failure Progression - the Prospective PEDAL-HF Study · NA · not yet recruiting
- NCT06526013 — Cholesterol Self-testing in Patients Post Acute Coronary Syndrome · NA · recruiting
- NCT06420622 — INDIcators for Clarifying the bAckground of exTreme Obesity in childRen · recruiting
- NCT06269263 — Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05178342 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leipzig
- Last refreshed: 13 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05178342.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing